Abstract

GlaxoSmithKline aims to sell almost one-third of its 370,000 m 2 R&D site in Stevenage, England, so that the land can be transformed into a biotech science campus. GSK says the plan could unlock up to $470 million of private investment and create up to 5,000 skilled jobs this decade. GSK hopes detailed planning for the campus will begin in 2022. A number of other organizations are already at the site, including the UK government’s Cell and Gene Therapy Catapult and some biotech start-ups.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.